APLN and prostate cancer: Apelin (APLN), an endogenous ligand of the APJ receptor, is aberrantly overexpressed in diverse malignancies, including glioblastoma [14], esophageal cancer [15, 16], hepatocellular carcinoma [17], and prostate cancer [18].